✦ LIBER ✦

Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G

✍ Scribed by Antonios C. Kattamis; Sadhna Shankar; Alan R. Cohen

Book ID: 117165834
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 250 KB
Volume: 130
Category: Article
ISSN: 1097-6833
DOI: 10.1016/s0022-3476(97)70355-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hemiplegia as a complication of treatmen

Hemiplegia as a complication of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin

✍ John Tsiouris; Nick Tsiouris 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Treatment of chronic childhood immune th

Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunoglobulins

✍ Caterina Borgna-Pignatti; Laura Battisti; Marco Zecca; Franco Locatelli 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Treatment of childhood acute immune thro

Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin

✍ Michael D. Tarantino; Renée M. Madden; D.Lucille Fennewald; Chandrakant C. Patel 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 156 KB

A prospective, randomized trial of high-

A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura

✍ Victor S. Blanchette; Brian Luke; Maureen Andrew; Sharon Sommerville-Nielsen; Do 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 628 KB

Safety and tolerability of a novel chrom

Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura

✍ James B. Bussel; Kim Hanna 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract Intravenous immunoglobulin (IGIV) therapy is generally considered to be a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP). The usual initial treatment dose is 1–2 g/kg body weight, which results in an extended infusion time, significantly impacting patients' d

Treatment of hematologic disorders other

Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg) — report of seven cases and review of the literature

✍ Yaniv Sherer; Yair Levy; Fabrizio Fabbrizzi; Yehuda Shoenfeld 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 54 KB